BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed GILD catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:1162ccf184da7abada18@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:GILD P3 readout (est.): Asian Study of Sacituzumab Govitecan (IMMU-
 132) in HR+/HER2- Metastatic Breast Cancer (MBC)
DESCRIPTION:Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Me
 tastatic Breast Cancer (MBC)\nNCT04639986 | PHASE3 | ACTIVE_NOT_RECRUITING
  | sponsor: Gilead Sciences\nPrimary completion date (ESTIMATED)\; top-lin
 e results usually follow later.\nDate precision: month (shown on the first
  day)\nTicker GILD (confidence 0.9)\nSource: https://clinicaltrials.gov/st
 udy/NCT04639986\nScheduling/reference data from public records\; dates can
  move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04639986
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9ee860ce0c0025306744@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:GILD P2 readout (est.): PALEKONA
DESCRIPTION:Study of Tilpisertib Fosmecarbil in Participants With Moderatel
 y to Severely Active Ulcerative Colitis\nNCT06029972 | PHASE2 | ACTIVE_NOT
 _RECRUITING | sponsor: Gilead Sciences\nPrimary completion date (ESTIMATED
 )\; top-line results usually follow later.\nDate precision: month (shown o
 n the first day)\nTicker GILD (confidence 0.9)\nSource: https://clinicaltr
 ials.gov/study/NCT06029972\nScheduling/reference data from public records\
 ; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06029972
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:51d330b198526f63033c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:GILD P3 readout (est.): ASCENT-04
DESCRIPTION:Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Tr
 eatment of Physician's Choice and Pembrolizumab in Patients With Previousl
 y Untreated\, Locally Advanced Inoperable or Metastatic Triple-Negative Br
 east Cancer\nNCT05382286 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Gilea
 d Sciences\nPrimary completion date (ESTIMATED)\; top-line results usually
  follow later.\nDate precision: month (shown on the first day)\nTicker GIL
 D (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT05382286\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05382286
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:367d8b0a437877c77703@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260827
DTEND;VALUE=DATE:20260828
SUMMARY:GILD APPROVAL: BIXLENVO
DESCRIPTION:Approved 2026-08-27: BIXLENVO (NDA221104 ORIG1)\nConfidence: co
 nfirmed\nTicker GILD (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=221104\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=221104
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:14370f43179cb92a78d6@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260827
DTEND;VALUE=DATE:20260828
SUMMARY:GILD APPROVAL: BIXLENVO SUNLENCA STARTER PACK (COPACKAGED)
DESCRIPTION:Approved 2026-08-27: BIXLENVO SUNLENCA STARTER PACK (COPACKAGED
 ) (NDA221443 ORIG1)\nConfidence: confirmed\nTicker GILD (confidence 0.9)\n
 Source: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=ov
 erview.process&ApplNo=221443\nScheduling/reference data from public record
 s\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=221443
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:ee3083ae65a1c90becf5@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260827
DTEND;VALUE=DATE:20260828
SUMMARY:GILD APPROVAL: SUNLENCA
DESCRIPTION:Approved 2026-08-27: SUNLENCA (NDA215973 SUPPL24)\nConfidence: 
 confirmed\nTicker GILD (confidence 0.9)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215973\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215973
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:bdc44aaece0fc0fe64cb@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260827
DTEND;VALUE=DATE:20260828
SUMMARY:GILD APPROVAL: SUNLENCA
DESCRIPTION:Approved 2026-08-27: SUNLENCA (NDA215974 SUPPL17)\nConfidence: 
 confirmed\nTicker GILD (confidence 0.9)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215974\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215974
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:fb40689059f224aac192@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260522
DTEND;VALUE=DATE:20260523
SUMMARY:GILD APPROVAL: HEPCLUDEX
DESCRIPTION:Approved 2026-05-22: HEPCLUDEX (BLA761468 ORIG1)\nConfidence: c
 onfirmed\nTicker GILD (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761468\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761468
CATEGORIES:approval,confirmed
END:VEVENT
END:VCALENDAR
